Amplify Seymour Cannabis ETF

CNBS

시가총액 US$6228만

The Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) has rallied sharply in 2026, with shares up 105% over the past year and 9% in just the last week.

Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.

Federal cannabis policy moved from theory to action this spring, and three ETFs sit closest to the trade.

Cannabis stocks have seen renewed investor interest as federal policy momentum improves. The most important recent development was the placement of FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act.

Cannabis ETFs entered 2026 after multiple fund closures, stalled federal reform, and a prolonged multi‑year drawdown in underlying equities.

Amplify Seymour Cannabis ETF (NYSEARCA:CNBS) posted a 17% gain in 2025, but that masks the real story.

Amplify Seymour Cannabis ETF (CNBS) is positioned for upside as U.S. cannabis reclassification to Schedule III appears likely, marking a key industry milestone. CNBS exhibits extreme volatility, warranting only a small (1-3%) portfolio allocation; call options are not attractive due to high premiums. Current CNBS valuations—12x trailing earnings and 3x sales—are reasonable for a growth sector anticipating regulatory tailwinds.

CNBS Cannabis ETF climbs to a 52-week high, fueled by rescheduling optimism and potential further gains.

I recommend buying cannabis sector ETFs. Recent news suggests imminent U.S. regulatory easing, potentially reclassifying marijuana and unlocking significant sector value. Current MJ ETF price/sales is 1.5x; I conservatively project a move to 2.5x, implying 66% upside. Key risks include regulatory uncertainty, sector profitability challenges, and historical underperformance post-IPOs.

Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.